Paul Kenna

Fondatore presso Spark Therapeutics Ireland Ltd.

Consumer Services

Health Technology

Profilo

Paul Kenna is the founder of Spark Therapeutics Ireland Ltd.
He is currently the Director-Ocular Genetics Unit at Trinity College Dublin since 2011.
Additionally, he holds positions as a Member at The Royal College of Physicians and the Irish College of Ophthalmologists.
Dr. Kenna obtained a doctorate degree from Trinity College Dublin.

Posizioni attive di Paul Kenna

Società	Posizione	Inizio
Spark Therapeutics Ireland Ltd. Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland.	Fondatore	-
Trinity College Dublin	Corporate Officer/Principal	-
The Royal College of Physicians	Corporate Officer/Principal	-
Irish College of Ophthalmologists	Corporate Officer/Principal	-

Tutte le posizioni attive di Paul Kenna

Formazione di Paul Kenna

Trinity College Dublin

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Paul Kenna

Relazioni

100 +

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
Spark Therapeutics Ireland Ltd. Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland.	Health Technology